NEXGEL, INC. (NXGL)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch NXGL
See up to 3 months of NXGL. The 7-day demo opens the 1M and 3M ranges and puts NXGL on your watchlist.
Start 7-day demoLatest NXGL insider trades
Adam R. Levy - OfficerOpen-market sale$4K
About NEXGEL, INC. (NXGL)
NEXGEL, INC. files with the SEC under CIK 0001468929 and is classified as surgical and medical instruments and apparatus. We track it alongside the rest of the Health Care sector. It filed a registration statement with the SEC on 20 August 2026 and has not yet priced an offering.
NXGL Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 160,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
NXGL insider transactions (Form 4)
4023 Form 4 filings on record, the earliest from Nov 22, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Adam R. Levy - Officer | Grant or award | Stock Option (Right to Buy) | 160,000 | $0.00 | - | |
| Adam R. Levy - Officer | Open-market sale | Common Stock | 6,000 | $0.59 footnote F1 | $4K | |
| Adam R. Levy - Officer | Open-market sale | Common Stock | 5,000 | $0.59 footnote F2 | $3K | |
| ||||||
| Adam R. Levy - Officer | Open-market sale | Common Stock | 3,000 | $0.61 footnote F1 | $2K | |
| ||||||
| Adam R. Levy - Officer | Open-market sale | Common Stock | 3,000 | $0.59 footnote F1 | $2K | |
| Adam R. Levy - Officer | Open-market sale | Common Stock | 3,000 | $0.55 footnote F2 | $2K | |
| ||||||
| Adam R. Levy - Officer | Open-market sale | Common Stock | 2,000 | $0.59 footnote F1 | $1K | |
| ||||||
| Adam R. Levy - Officer | Open-market sale | Common Stock | 3,000 | $0.60 footnote F1 | $2K | |
| Adam R. Levy - Officer | Open-market sale | Common Stock | 7,000 | $0.61 footnote F2 | $4K | |
| Adam R. Levy - Officer | Open-market sale | Common Stock | 3,000 | $0.60 footnote F3 | $2K | |
| ||||||
| Scott Robert Henry - Director | Open-market purchase | Convertible Promissory Note (the "Note") | 41,667 | $0.60 | $25K | |
| Scott Robert Henry - Director | Open-market purchase | Warrant to Purchase Common Stock (the "Warrant") | 20,834 | $0.00 footnote F2 | - | |
| ||||||
| Brian Joseph Kieser - Director | Open-market purchase | Convertible Promissory Note (the "Note") | 1,666,667 | $0.60 | $1.00M | |
| Brian Joseph Kieser - Director | Open-market purchase | Warrant to Purchase Common Stock (the "Warrant") | 833,334 | $0.00 footnote F2 | - | |
| ||||||
| Adam R. Levy - Officer | Open-market purchase | Convertible Promissory Note (the "Note") | 100,000 | $0.60 | $60K | |
| Adam R. Levy - Officer | Open-market purchase | Warrant to Purchase Common Stock (the "Warrant") | 50,000 | $0.00 footnote F2 | - | |
| ||||||
| Adam R. Levy - Officer | Open-market sale | Common Stock | 6,000 footnote F1 | $1.61 footnote F2 | $10K | |
| Adam R. Levy - Officer | Open-market sale | Common Stock | 4,000 footnote F1 | $1.57 footnote F3 | $6K | |
| ||||||
| Adam R. Levy - Officer | Open-market sale | Common Stock | 4,000 footnote F1 | $2.52 footnote F2 | $10K | |
| ||||||
| Scott Robert Henry - Director | Open-market sale | Common Stock | 825 footnote F1 | $2.50 footnote F2 | $2K | |
| Scott Robert Henry - Director | Open-market sale | Common Stock | 7,175 footnote F1 | $2.55 footnote F3 | $18K | |
| ||||||
| Adam R. Levy - Officer | Open-market sale | Common Stock | 1,600 footnote F1 | $2.50 footnote F2 | $4K | |
| Adam R. Levy - Officer | Open-market sale | Common Stock | 2,400 footnote F1 | $2.55 footnote F3 | $6K | |
| ||||||
| Scott Robert Henry - Director | Open-market sale | Common Stock | 7,697 | $2.36 | $18K | |
| Adam R. Levy - Officer | Open-market sale | Common Stock | 4,000 | $2.47 | $10K | |
| John Nachum Stein - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Scott Robert Henry - Director | Open-market sale | Common Stock | 3,000 | $4.64 | $14K | |
| Adam E. Drapczuk III - Officer | Open-market purchase | Common Stock | 17,500 | $2.75 | $48K | |
| Adam E. Drapczuk III - Officer | Grant or award | Warrant to Purchase Common Stock | 8,750 | $0.00 | - | |
| Steven Mark Glassman - Director | Open-market purchase | Common Stock | 9,090 | $2.75 | $25K | |
| Steven Mark Glassman - Director | Grant or award | Warrant to Purchase Common Stock | 4,545 | $0.00 | - | |
| Scott Robert Henry - Director | Open-market purchase | Common Stock | 1,818 | $2.75 | $5K | |
| Scott Robert Henry - Director | Grant or award | Warrant to Purchase Common Stock | 909 | $0.00 | - | |
| Adam R. Levy - Officer | Open-market purchase | Common Stock | 3,636 | $2.75 | $10K | |
| Adam R. Levy - Officer | Grant or award | Warrant to Purchase Common Stock | 1,818 | $0.00 | - | |
| Jerome B. Zeldis - Director | Open-market purchase | Common Stock | 3,636 | $2.75 | $10K | |
| Jerome B. Zeldis - Director | Grant or award | Warrant to Purchase Common Stock | 1,818 | $0.00 | - | |
| John Nachum Stein - Director | Gift | Common Stock | 4,000 | $0.00 | - | |
| John Nachum Stein - Director | Open-market purchase | Common Stock | 3,636 | $2.75 | $10K | |
| John Nachum Stein - Director | Grant or award | Warrant to Purchase Common Stock | 1,818 | $0.00 | - | |
Item 3.03, 5.03, 9.01
Item 7.01, 9.01
Item 5.07, 9.01
Item 5.02, 9.01
Recent NXGL Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Levy Adam R. | Affilaite | 21,500 | $3K | View on EDGAR | |
| - | - | - | - |
NXGL insider trading FAQ
What is the latest insider trade for NXGL?
NEXGEL, INC. (NXGL) had 1 insider filing in the last 90 days, with the most recent on 2026-07-29. The full record for NXGL runs to 23 Form 4 filings, the earliest from 2024-11-22. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying NXGL stock?
No insider purchases of NXGL were filed in the last 90 days. 12 purchases are on record for this company.
How many insiders are selling NXGL stock?
No insider sales of NXGL were filed in the last 90 days. 19 sales are on record for this company.
Where can I see NXGL SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects NXGL Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Adam R. Levy view on EDGAR
- - Adam R. Levy view on EDGAR
- - Adam R. Levy view on EDGAR
- - Adam R. Levy view on EDGAR
- - Adam R. Levy view on EDGAR
- - Adam R. Levy view on EDGAR
- - Scott Robert Henry view on EDGAR
- - Brian Joseph Kieser view on EDGAR
- - Adam R. Levy view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where NXGL's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow NXGL with a 7-day demo
- NXGL on your watchlist
- Every NXGL Form 4 filing on record
- Up to 3 months of NXGL price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
